Literature DB >> 26829271

Comparison of the efficacy of prednisone and cyclosporine for treatment of dogs with primary immune-mediated polyarthritis.

Amy C Rhoades, William Vernau, Philip H Kass, Melissa A Herrera, Jane E Sykes.   

Abstract

OBJECTIVE: To compare efficacy between cyclosporine and prednisone for treatment of primary immune-mediated polyarthritis (IMPA) in dogs.
DESIGN: Randomized controlled clinical trial. ANIMALS: 20 client-owned dogs with primary IMPA. PROCEDURES: Dogs were randomly assigned to receive prednisone (starting at 1 mg/kg [0.45 mg/lb], PO, q 12 h; n = 10) or cyclosporine (5 mg/kg [2.3 mg/lb], PO, q 12 h; 10) for 90 days. Cyclosporine-treated dogs also received carprofen, tramadol, or both for the first 7 days for analgesia. Data collection, physical examination, and cytologic analysis of synovial fluid samples were performed on days 0, 14, 45, and 90. Trough whole blood cyclosporine concentrations were determined on days 7 to 17 for cyclosporine-treated dogs. Treatment failure was defined as lack of clinical improvement by day 14, lack of cytologic improvement by day 45, or need to change treatment because of adverse effects.
RESULTS: Treatment was successful for 7 prednisone-treated dogs and 7 cyclosporine-treated dogs. Absence of synovial fluid cytologic abnormalities on day 45 was identified for 5 prednisone-treated dogs and 8 cyclosporine-treated dogs. Prednisone-treated dogs were more likely to develop polyuria, polydipsia, and polyphagia than were cyclosporine-treated dogs. Opportunistic infections (ie, demodicosis or Erysipelothrix bacteremia) were identified in 2 cyclosporine-treated dogs and 0 prednisone-treated dogs, and diarrhea developed in 1 cyclosporine-treated dog, requiring treatment discontinuation. CONCLUSIONS AND CLINICAL RELEVANCE: Although the number of dogs evaluated was small, limiting generalizability, results of this study suggested that cyclosporine offers promise as a suitable alternative to prednisone for treatment of IMPA in dogs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26829271     DOI: 10.2460/javma.248.4.395

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  9 in total

1.  The prevalence of bacterial infections during cyclosporine therapy in dogs: A critically appraised topic.

Authors:  Endya J High; Thierry Olivry
Journal:  Can Vet J       Date:  2020-12       Impact factor: 1.008

2.  Increased risk of select glucocorticoid adverse events in dogs of higher body weight.

Authors:  Loren S Sri-Jayantha; Michael T Doornink; Bridget K Urie
Journal:  Can Vet J       Date:  2022-01       Impact factor: 1.008

3.  Recovery of T-cell function in healthy dogs following cessation of oral cyclosporine administration.

Authors:  Lakshmi Narayanan; Charlee Mulligan; Lisa Durso; Brittany Thames; John Thomason; Claire Fellman; Andrew Mackin; Robert Wills; Todd Archer
Journal:  Vet Med Sci       Date:  2020-01-08

4.  Salmonella enterica serovar Typhimurium isolated from the urine of a dog undergoing treatment for immune-mediated polyarthritis.

Authors:  Stephen D Cole; Shannon M Palermo; Shelley C Rankin
Journal:  JMM Case Rep       Date:  2018-05-08

5.  ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.

Authors:  James W Swann; Oliver A Garden; Claire L Fellman; Barbara Glanemann; Robert Goggs; Dana N LeVine; Andrew J Mackin; Nathaniel T Whitley
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

6.  Retrospective evaluation of cyclosporine in the treatment of presumed idiopathic chronic hepatitis in dogs.

Authors:  Tarini Ullal; Yoko Ambrosini; Sangeeta Rao; Cynthia R L Webster; David Twedt
Journal:  J Vet Intern Med       Date:  2019-08-08       Impact factor: 3.333

7.  Investigation of single-nucleotide polymorphisms in the NR3C1a glucocorticoid receptor gene in Cocker Spaniels with primary immune thrombocytopenia.

Authors:  Sarah Tayler; Katarina Hazuchova; Anna Riddle; James W Swann; Barbara Glanemann
Journal:  J Vet Intern Med       Date:  2022-06-10       Impact factor: 3.175

8.  Point prevalence and clinical course of proteinuria in dogs with idiopathic non-erosive immune-mediated polyarthritis.

Authors:  L Barker; S McManus; S Adamantos; V Black
Journal:  J Small Anim Pract       Date:  2022-05-04       Impact factor: 1.669

9.  Ehrlichia canis in dogs experimentally infected, treated, and then immune suppressed during the acute or subclinical phases.

Authors:  Masahiko Sato; Julia K Veir; Sarah B Shropshire; Michael R Lappin
Journal:  J Vet Intern Med       Date:  2020-04-08       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.